DelveInsight’s, “Dry Age-Related Macular Degeneration Pipeline Insight, 2023,” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Dry Age-Related Macular Degeneration pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Dry Age-Related Macular Degeneration pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Dry Age-Related Macular Degeneration NDA approvals (if any), and product development activities comprising the technology, Dry Age-Related Macular Degeneration collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Dry Age-Related Macular Degeneration Pipeline Report
To explore more information on the latest breakthroughs in the Dry Age-related Macular Degeneration Pipeline treatment landscape of the report, click here @ Dry Age-related Macular Degeneration Pipeline Outlook
Dry Age-related Macular Degeneration Overview
Age-related macular degeneration (AMD) is a degenerative disease of the center area of the ocular-posterior segment (the macula lutea) that causes slow degeneration in central vision and severe disability in affected persons. “Age-related” means that it mainly occurs with elderly adults, while “Macular” means that the macula part of the eye is damaged. AMD mostly affects people aged above 50, and it was first reported more than 80 years ago. Dry macular degeneration is a common eye disorder among people aged above 50 years. It causes blurred or reduced central vision due to thinning of the macula. The macula is the part of the retina responsible for clear vision in a direct line of sight. GA or choroidal neovascularization are two processes that produce photoreceptor failure in late AMD and can cause visual loss.
Recent Developments Activities in the Dry Age- related Macular Degeneration Treatment Landscape
Request a sample and discover the recent advances in Dry Age-related Macular Degeneration Ongoing Clinical Trial Analysis and Medications, click here @ Dry Age-related Macular Degeneration Treatment Landscape
Dry Age-Related Macular Degeneration Emerging Drugs Profile
ALK-001: Alkeus Pharmaceuticals
ALK-001 is once-a-day oral drug candidate currently being tested in Phase III clinical trial for the treatment of geographic atrophy (advanced form of AMD) and Stargardt disease. Toxic vitamin A aggregates called “”dimers”” are known to rapidly form due to a genetic defect in Stargardt, or to accumulate with age in the case of dry AMD. These toxic dimers have been implicated in the degeneration of the retina seen in Stargardt and AMD. Dimers form when two molecules of vitamin A are chemically combined. ALK-001 is form of vitamin A that has been chemically-modified to prevent its aggregation into dimers.
Zimura: Iveric bio
Zimura (avacincaptad pegol) is an investigational drug product designed to target and inhibit the cleavage of complement protein C5 and the formation of its downstream fragments, C5a and C5b. By inhibiting the formation of these fragments, Zimura is believed to decrease or slow the chronic inflammation and cell death associated with the retinal aging process by decreasing the formation of membrane attack complex (MAC) and inflammasome activity, thereby potentially avoiding or slowing the degeneration of retinal pigment epithelial cells.
Visomitin: Mitotech
Visomitin is an eye drop formulation of SkQ1 that has been developed to target ophthalmic disorders like dry eye syndrome, uveitis and age-related macular degeneration. SkQ1 – is a purposely designed cardiolipin peroxidation inhibitor. SkQ1 was developed to deliver a highly active antioxidant plastoquinone into mitochondria. Once positioned in mitochondria, the molecule acts as a mitochondria-targeted ROS scavenger in general and as a very efficient cardiolipin protector in particular.
Risuteganib: Allegro Ophthalmics
Risuteganib is an investigational integrin-regulating therapy that is believed to reduce mitochondrial dysfunction involved in intermediate dry AMD. By targeting multiple pathways, risuteganib may help reduce the cellular burden of oxidative stress and restore retinal homeostasis. Two concurrent Phase 3 studies evaluating the use of intravitreal risuteganib to treat intermediate dry AMD are expected to begin within the next 12 months. A Phase II clinical trial evaluating risuteganib in Dry AMD has been completed by allegro Ophthalmics.
GT005: Gyroscope Therapeutics
Gyroscope’s lead investigational gene therapy, GT005, is a one-time therapy delivered under the retina. An overactive complement system has been implicated in the development of AMD. GT005 is designed to restore balance to an overactive complement system, a part of the immune system, by increasing production of the CFI protein. The CFI protein regulates the activity of the complement system. It is believed that increasing CFI production will dampen the systems over activity and reduce inflammation, with the goal of preserving a person’s eyesight. Gyroscope’s lead candidate, GT005, is currently in two Phase IIs for patients with geographic atrophy, an irreversible degeneration of retinal cells caused by dry-AMD.
GEM103: Gemini Therapeutics
Gemini’s lead program, GEM103, is a pioneering precision medicine approach, targeting trial enrichment with genetically-defined patients. GEM103 targets a genetically-defined subset of age-related macular degeneration (AMD) patients with complement dysregulation. GEM103 is believed to be the first ever recombinant native complement modulator, full-length recombinant complement factor H (rCFH) protein. When delivered by intravitreal injection, GEM103 has the potential to address unmet medical need in genetically-defined subsets of AMD patients by circumventing dysfunctional CFH loss-of-function variants and slowing the progression of their retinal disease. A Phase II clinical trial is currently being evaluated to treat patients with Dry AMD and other retinal disease.
Dry Age-related Macular Degeneration Pipeline Therapeutics Assessment
There are approx. 40+ key companies which are developing the therapies for Dry Age-Related Macular Degeneration. The companies which have their Dry Age-Related Macular Degeneration drug candidates in the most advanced stage, i.e. Phase III include, Alkeus Pharmaceuticals.
For further information, refer to the detailed Dry Age-related Macular Degeneration Unmet Needs, Dry Age-related Macular Degeneration Market Drivers, and Market Barriers, click here for Dry Age-related Macular Degeneration Ongoing Clinical Trial Analysis
Scope of the Dry Age-related Macular Degeneration Pipeline Report
Dive deep into rich insights for drugs for Dry Age-related Macular Degeneration Market Drivers and Dry Age-related Macular Degeneration Market Barriers, click here @ Dry Age-related Macular Degeneration Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Dry Age-related Macular Degeneration Mergers and acquisitions, Dry Age-related Macular Degeneration Licensing activities @ Dry Age-related Macular Degeneration Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services